De-escalating Axillary Surgery in Breast Cancer Patients in Nigeria
Breast Cancer, Axilla; Breast
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring neoadjuvant, de-escalation, breast cancer, axillary lymph node staging
Eligibility Criteria
Inclusion Criteria: Eligible to receive systemic chemotherapy Must include all the following: Tany, cN1 at presentation Biopsy proven pN1 disease after axillary US cN0 after neoadjuvant chemotherapy Exclusion Criteria: Previous / recurrent breast cancer Previous axillary and/or breast surgery Inflammatory breast cancer N2 disease or Stage IV disease
Sites / Locations
Arms of the Study
Arm 1
Other
Sentinel Lymph Node Biopsy Arm
Patients with non-metastatic, biopsy and clipped locally advanced breast cancer will start systemic chemotherapy as per institutional best practices. Patients with a clinical complete response will be consented for SLNB followed by immediate ALND. Patients with persistent suspicious clinical adenopathy will be consented for ALND alone. All patients regardless of response to NAC will undergo ALND as per current institutional practices. Patients undergoing SLNB followed by ALND will have the procedure performed by study the co-PI at OAUTH who is trained in the performance of SLNB. Histopathologic assessment of the breast and axillary contents will follow a standardized reporting procedure, including the assessment of residual cancer burden in both the breast and the axilla. Presence or absence of residual disease will be reported separately for the SLNB specimens, clipped node and remaining axillary contents.